Gene · 1909
Papers4,314
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
481 to 500 of 4,314
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Targeting Immune-Fibroblast Crosstalk in Myocardial Infarction and Cardiac Fibrosis. | Res Sq | 2023 | 36747878 | PubTator, text mining | PubMed |
| Airway remodeling heterogeneity in asthma and its relationship to disease outcomes. | Front Physiol | 2023 | 36744026 | PubTator, text mining | PubMed |
| Novel biomarkers and emerging tools to identify causal molecular pathways in hypertension and associated cardiovascular diseases. | Kardiol Pol | 2023 | 36739654 | PubTator, text mining | PubMed |
| Biomechanical and Mechanobiological Drivers of the Transition From PostCapillary Pulmonary Hypertension to Combined Pre-/PostCapillary Pulmonary Hypertension. | J Am Heart Assoc | 2023 | 36734341 | PubTator, text mining | PubMed |
| A Narrative Review of New Treatment Options for Diabetic Nephropathy. | Cureus | 2023 | 36733548 | PubTator, text mining | PubMed |
| Investigation of the keratinocyte transcriptome altered in high-glucose environment: An in-vitro model system for precision medicine. | J Dermatol Sci | 2023 | 36725459 | PubTator, text mining | PubMed |
| The non-selective Rho-kinase inhibitors Y-27632 and Y-33075 decrease contraction but increase migration in murine and human hepatic stellate cells. | PLoS One | 2023 | 36719899 | PubTator, text mining | PubMed |
| The interaction of β-arrestin1 with talin1 driven by endothelin A receptor as a feature of α5β1 integrin activation in high-grade serous ovarian cancer. | Cell Death Dis | 2023 | 36717550 | PubTator, text mining | PubMed |
| Protective effect of urotensin II receptor antagonist urantide and exercise training on doxorubicin-induced cardiotoxicity. | Sci Rep | 2023 | 36690700 | PubTator, text mining | PubMed |
| Ca2+-Activated K+ Channels and the Regulation of the Uteroplacental Circulation. | Int J Mol Sci | 2023 | 36674858 | PubTator, text mining | PubMed |
| Screening potential ligands of endothelin receptor A from Choerospondias axillaris and evaluation of their drug-like properties by affinity chromatographic methods. | J Pharm Biomed Anal | 2023 | 36657350 | PubTator, text mining | PubMed |
| Brain activity during a working memory task after daily caffeine intake and caffeine withdrawal: a randomized double-blind placebo-controlled trial. | Sci Rep | 2023 | 36653409 | PubTator, text mining | PubMed |
| Specific Autoantibodies and Microvascular Damage Progression Assessed by Nailfold Videocapillaroscopy in Systemic Sclerosis: Are There Peculiar Associations? An Update. | Antibodies (Basel) | 2023 | 36648887 | PubTator, text mining | PubMed |
| Rejection markers in kidney transplantation: do new technologies help children? | Pediatr Nephrol | 2023 | 36648536 | PubTator, text mining | PubMed |
| Novel Treatment Paradigms: Focal Segmental Glomerulosclerosis. | Kidney Int Rep | 2023 | 36644367 | PubTator, text mining | PubMed |
| Mandibulofacial dysostosis with alopecia results from ETAR gain-of-function mutations via allosteric effects on ligand binding. | J Clin Invest | 2023 | 36637912 | PubTator, text mining | PubMed |
| Genetic, DNA methylation, and immune profile discrepancies between early-stage single primary lung cancer and synchronous multiple primary lung cancer. | Clin Epigenetics | 2023 | 36611170 | PubTator, text mining | PubMed |
| Targeting tumor-stroma communication by blocking endothelin-1 receptors sensitizes high-grade serous ovarian cancer to PARP inhibition. | Cell Death Dis | 2023 | 36604418 | PubTator, text mining | PubMed |
| Targeting integrin pathways: mechanisms and advances in therapy. | Signal Transduct Target Ther | 2023 | 36588107 | PubTator, text mining | PubMed |
| Non-ionic cholesterol-based additives for the stabilization of membrane proteins. | Biochimie | 2023 | 36586567 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/1909/papers?page=25